Exchange Traded Concepts LLC Acquires New Position in Metsera Inc. $MTSR

Key Points

• Exchange Traded Concepts LLC has acquired a new stake in Metsera Inc. (NASDAQ:MTSR), purchasing 40,528 shares valued at approximately $1.15 million in the second quarter.
• Institutional investors have shown significant interest in Metsera, with Alphabet Inc. acquiring a considerable stake valued at about $135 million in the first quarter.
• Metsera's stock is currently trading at $53.58, with analysts assigning a consensus rating of "Buy" and an average target price of $63.50.

Exchange Traded Concepts LLC acquired a new stake in Metsera Inc. (NASDAQ:MTSR - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 40,528 shares of the company's stock, valued at approximately $1,153,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in MTSR. Bank of New York Mellon Corp acquired a new stake in shares of Metsera in the first quarter valued at about $884,000. New York State Common Retirement Fund acquired a new stake in shares of Metsera in the first quarter valued at about $131,000. Alphabet Inc. acquired a new stake in shares of Metsera in the first quarter valued at about $135,059,000. Massachusetts Financial Services Co. MA acquired a new stake in shares of Metsera in the first quarter valued at about $13,111,000. Finally, Jennison Associates LLC acquired a new stake in shares of Metsera in the first quarter valued at about $9,679,000.

Metsera Stock Performance

Metsera stock opened at $53.58 on Tuesday. Metsera Inc. has a 1 year low of $12.30 and a 1 year high of $54.47. The firm has a 50 day moving average price of $35.71 and a 200 day moving average price of $29.35.

Metsera (NASDAQ:MTSR - Get Free Report) last released its quarterly earnings data on Monday, July 28th. The company reported ($0.66) earnings per share (EPS) for the quarter.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Bank of America raised their price objective on shares of Metsera from $45.00 to $50.00 and gave the company a "buy" rating in a research note on Thursday, August 28th. Leerink Partnrs upgraded shares of Metsera to a "strong-buy" rating in a report on Tuesday, September 9th. Wall Street Zen downgraded shares of Metsera from a "hold" rating to a "sell" rating in a report on Tuesday. Cantor Fitzgerald restated an "overweight" rating on shares of Metsera in a report on Wednesday, September 3rd. Finally, Guggenheim raised their target price on shares of Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a report on Tuesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $63.50.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

Want to see what other hedge funds are holding MTSR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Metsera Inc. (NASDAQ:MTSR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.